痛风
非布索坦
医学
别嘌呤醇
尿酸
黄嘌呤氧化酶
化脓性关节炎
高尿酸血症
关节炎
重症监护医学
黄嘌呤氧化酶抑制剂
痛风性关节炎
炎性关节炎
内科学
外科
生物化学
化学
酶
作者
Abhishek Abhishek,Edward Roddy,Michael Doherty
出处
期刊:Clinical Medicine
[Royal College of Physicians]
日期:2017-02-01
卷期号:17 (1): 54-59
被引量:95
标识
DOI:10.7861/clinmedicine.17-1-54
摘要
ABSTRACT
Gout is the most prevalent inflammatory arthritis and affects 2.5% of the general population in the UK. It is also the only arthritis that has the potential to be cured with safe, inexpensive and well tolerated urate-lowering treatments, which reduce serum uric acid by either inhibiting xanthine oxidase – eg allopurinol, febuxostat – or by increasing the renal excretion of uric acid. Of these, xanthine oxidase inhibitors are used first line and are effective in 'curing' gout in the vast majority of patients. Gout can be diagnosed on clinical grounds in those with typical podagra. However, in those with involvement of other joints, joint aspiration is recommended to demonstrate monosodium urate crystals and exclude other causes of acute arthritis, such as septic arthritis. However, a clinical diagnosis of gout can be made if joint aspiration is not feasible. This review summarises the current understanding of the pathophysiology, clinical presentation, investigations and treatment of gout.
科研通智能强力驱动
Strongly Powered by AbleSci AI